SPONSORED CONTENT: As CDMOs face increasing demand for agility and resilience, Azam Razzaq from FUJIFILM Biotechnologies reveals how the expanded Borealis facility is helping to bridge the gap between clinical supply and commercial reality for sponsors.

The expansion of the Swiss CDMO’s activities into the Asia Pacific area marks a significant milestone in its global growth and means it will be able to better serve pharma and biotech companies across the region.

In response to the growing demand for in-human trial material, German CDMO Vetter is expanding its clinical manufacturing network with new infrastructure in the U.S. and Austria.

The new service, which is available at Lonza’s Singapore site, aims to help bioprocessing customers improve scalability, reduce manufacturing risk, and accelerate development timelines.

Plans for a further 3,000-square-metre spray drying and high-potency containment unit at Celrà facility in Girona, Spain, have been announced by the CDMO.

The company will add new reactor suites to its Delaware campus, increasing its API reactor capacity by more than double and enabling the company to meet new demand for high-quality domestic manufacturing.

The German contract manufacturer is expanding its lyophilization capacity with a complete production line from equipment supplier Syntegon, as demand for sterile freeze-dried pharmaceuticals continues to grow across the sector.

With support from LSIMF, Codis is expanding its UK facility with the addition of a GEA PSD-4 commercial-scale spray dryer, making it the only CDMO in the UK to offer such capacity.

The major USD 15.5 million upgrade at ESTEVE CDMO’s Morton Grove, Illinois plant, is expected to supercharge small-molecule API production for pharmaceutical and biotech clients across North America.

The USD 3.5 billion site reflects Lilly’s strategy to expand domestic capacity for glucagon-like peptide-1 (GLP‑1) drugs amid soaring demand and supply‑chain scrutiny.

The CDMO commits EUR 480 million to a new production facility on its Saarlouis site as it puts into action its long-term growth strategy to meet rising global biopharma demand.

The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

The CDMO has completed the expansion of its Pessano facility in Milan, Italy, adding increased packaging and warehousing capacity that has already been authorized by the AIFA and is producing validation and commercial batches.

Located in Stein, Switzerland, the new GMP licensed line will enable the company to provide integrated, end-to-end solutions for the whole biologics and bioconjugation value chain.

Through the strategic acquisition of a facility from WuXi Biologics based in Germany, Terumo has strengthened its ability to serve both domestic and international pharmaceutical companies.

Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.